New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
11:26 EDTTKPYY, SGENSeattle Genetics, Takeda report median OS 40.5 months in R/R HL with Adcetris
Seattle Genetics (SGEN) and Takeda Pharmaceutical (TKPYY) announced updated overall survival data from two ADCETRIS pivotal Phase 2 clinical trials in relapsed/refractory Hodgkin lymphoma, or R/R HL, and relapsed/refractory systemic anaplastic large cell lymphoma, or R/R sALCL, were presented at the 55th American Society of Hematology Annual Meeting taking place in New Orleans, LA, December 7-10. ADCETRIS is an antibody-drug conjugate directed to CD30. Median overall survival of 40.5 months was reported in R/R HL, and was not yet reached in R/R sALCL.
News For TKPYY;SGEN From The Last 14 Days
Check below for free stories on TKPYY;SGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
10:34 EDTTKPYYApricus Biosciences reports Takeda accepts first shipment of Vitaros
Subscribe for More Information
08:34 EDTSGENPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
April 8, 2014
09:03 EDTSGEN, TKPYYSeattle Genetics to receive milestone payments from Takeda on Adcetris
Subscribe for More Information
08:39 EDTTKPYYTakeda to challenge award of $6B in punitive damages, Lilly ordered to pay $3B
Takeda Pharmaceuticals (TKPYY) announced last night that in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America the jury found in favor of the plaintiffs and awarded $1.475M in compensatory damages. The allocation of liability was 75% Takeda and 25% Eli Lilly (LLY). The jury also awarded $6B in punitive damages from Takeda and $3B from co-defendant, Eli Lilly. “Takeda respectfully disagrees with the verdict and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal. We have empathy for the Allens, but we believe the evidence did not support a finding that ACTOS caused his bladder cancer. We also believe we demonstrated that Takeda acted responsibly with regard to ACTOS,” said Kenneth Greisman, senior vice president, general counsel, Takeda. Reference Link
07:35 EDTSGENNeedham to hold a conference
Life Sciences Conference is being held in New York on April 8-9.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use